When Daniel Fischer cofounded Tevard Biosciences in 2017, he wasn’t trying to bet on the next hot RNA technology. His interest was more personal. His daughter Natasha has Dravet syndrome, a rare form ...

For disorders driven by a known genetic component, research understandably focuses on developing a drug targeting that genetic signature. When that works, the outcome benefits patients but the end ...

Alltrna is the latest in a growing number of startups with plans to develop therapies based on transfer RNA (tRNA), a family of RNA molecules that play a vital role in building proteins. The Cambridge ...

HC Bioscience is shutting down after conducting preclinical models for a transfer RNA (tRNA) asset designed to treat hemophilia A. The Cambridge, Massachusetts-based biotech is closing “following ...